Eliglustat tartrate
酒石酸艾格司他Oral substrate reduction therapy for Gaucher disease type 1 whose 2026 NRDL entry adds pediatric coverage (age ≥6, ≥15 kg) and adjusts payment standard from ¥381.00 to ¥361.95.
China Approval (NMPA)
Pending VerificationReimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #41 · Class B
- Agreement Period
- 2027-01-01 to 2027-12-31
- Payment Standard
- 361.95元(84mg/粒(按C23H36N2O4计))
- 2026 Payment Scope
- Expanded to cover both adult GD1 patients and pediatric GD1 patients (age ≥6 years, weight ≥15 kg, stable on ERT) who are CYP2D6 PMs, IMs, or EMs; published standard adjusted from ¥381.00 to ¥361.95 per 84mg capsule.
- 限:1.经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者;2.6岁及以上,体重15公斤及以上,酶替代治疗(ERT)稳定,以及经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)儿童患者的治疗。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
2025 vs 2026 NRDL Payment Scope Comparison
Restricted to adult Gaucher disease type 1 (GD1) patients who are CYP2D6 poor, intermediate, or extensive metabolizers.
限经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者。
Expanded to cover both adult GD1 patients and pediatric GD1 patients (age ≥6 years, weight ≥15 kg, stable on ERT) who are CYP2D6 PMs, IMs, or EMs; published standard adjusted from ¥381.00 to ¥361.95 per 84mg capsule.
限:1.经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者;2.6岁及以上,体重15公斤及以上,酶替代治疗(ERT)稳定,以及经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)儿童患者的治疗。
Approved Products, Dosage Forms & Approval Numbers
0 verified NMPA recordsChange Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Payment Scope Updated
Expanded from adult Gaucher disease type 1 in 2025 (#38, ¥381.00) to add pediatric GD1 patients (age ≥6y, weight ≥15kg, ERT-stable) in 2026 (#41, ¥361.95 per 84mg capsule).
Chinese original: 支付范围新增6岁及以上且体重≥15公斤、ERT稳定的Ⅰ型戈谢病儿童患者,支付标准同步由381.00元调整为361.95元(84mg/粒)。
NHSA · PDF p.119Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07国家基本医疗保险、生育保险和工伤保险药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药品监督管理局政务服务门户与药品查询Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20